Concurrent Use of Tafamidis and Mavacamten for Transthyretin Cardiac Amyloidosis With Severe Outflow Tract Obstruction
Hemodynamically significant LVOT obstruction is a rare but clinically relevant manifestation of CA that may lead to diagnostic ambiguity and difficult management decisions. Tafamidis and mavacamten can be used safely in combination to provide symptom relief and slow disease progression in obstructive transthyretin CA.
Authors
- Joban Vaishnav (ORCID: https://orcid.org/0000-0001-5021-5454)
- Ali Asghar Kassamali
- Matthew J. Czarny (ORCID: https://orcid.org/0000-0002-8039-4956)
- José Madrazo (ORCID: https://orcid.org/0000-0002-9966-2703)
- Stefan L. Zimmerman (ORCID: https://orcid.org/0000-0002-9422-6742)
- Vrinda Gupta (ORCID: https://orcid.org/0000-0002-6743-8395)
- Richard Carrick (ORCID: https://orcid.org/0000-0001-5589-1216)
- Victoria Blake (ORCID: https://orcid.org/0000-0001-6237-3062)
- Jeremy Johnson
Institutions
- Kennedy Krieger Institute (US)
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Johns Hopkins Bayview Medical Center (US)
Publication Details
- Journal
- JACC Case Reports
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1016/j.jaccas.2025.104495
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health